Maybio Matrix

Maybio Matrix is a biopharmaceutical and biotechnology startup founded in 2019. The company is dedicated to advancing the future of maxillofacial tissue regeneration with innovative biological scaffold solutions for both medical and aesthetic applications. The description of the company highlights its focus on research and development, production, and sales of biological scaffold material tailored for maxillofacial tissue regeneration, addressing medical, plastic, and cosmetic clinical needs. Maybio Matrix recently secured a significant milestone by receiving a Series A investment on 14 September 2023. The investment was led by Caixin Industry Fund, Sunz Fund, and Xinhangcheng Holdings, showcasing a strong vote of confidence from prominent investors in the industry. This influx of capital is expected to fuel the company's growth and propel its innovative solutions into the market, potentially shaping the future of maxillofacial tissue regeneration. Overall, Maybio Matrix stands as a promising player in the biopharma and biotechnology industries, with a clear focus on pioneering solutions in the field of maxillofacial tissue regeneration. The recent Series A investment indicates a bright outlook for the company, highlighting its potential to make a significant impact in the medical and aesthetic realms.